Invention Application
WO2010146338A1 AMIDO-ISOTHIAZOLE COMPOUNDS AND THEIR USE AS INHIBITORS OF 11BETA-HSD1 FOR THE TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS
审中-公开
AMIDO-异噻唑化合物及其作为11BETA-HSD1的抑制剂用于治疗代谢综合症和相关疾病的用途
- Patent Title: AMIDO-ISOTHIAZOLE COMPOUNDS AND THEIR USE AS INHIBITORS OF 11BETA-HSD1 FOR THE TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS
- Patent Title (中): AMIDO-异噻唑化合物及其作为11BETA-HSD1的抑制剂用于治疗代谢综合症和相关疾病的用途
-
Application No.: PCT/GB2010/001155Application Date: 2010-06-14
-
Publication No.: WO2010146338A1Publication Date: 2010-12-23
- Inventor: WEBSTER, Scott, Peter , SECKL, Jonathan, Robert , WALKER, Brian, Robert , WARD, Peter , PALLIN, Thomas, David , DYKE, Hazel, Joan , PERRIOR, Trevor, Robert
- Applicant: THE UNIVERSITY OF EDINBURGH , WEBSTER, Scott, Peter , SECKL, Jonathan, Robert , WALKER, Brian, Robert , WARD, Peter , PALLIN, Thomas, David , DYKE, Hazel, Joan , PERRIOR, Trevor, Robert
- Applicant Address: Old College South Bridge Edinburgh EH8 9YL GB
- Assignee: THE UNIVERSITY OF EDINBURGH,WEBSTER, Scott, Peter,SECKL, Jonathan, Robert,WALKER, Brian, Robert,WARD, Peter,PALLIN, Thomas, David,DYKE, Hazel, Joan,PERRIOR, Trevor, Robert
- Current Assignee: THE UNIVERSITY OF EDINBURGH,WEBSTER, Scott, Peter,SECKL, Jonathan, Robert,WALKER, Brian, Robert,WARD, Peter,PALLIN, Thomas, David,DYKE, Hazel, Joan,PERRIOR, Trevor, Robert
- Current Assignee Address: Old College South Bridge Edinburgh EH8 9YL GB
- Agency: WYTENBURG, Wilhelmus et al.
- Priority: US61/186,963 20090615
- Main IPC: C07D417/06
- IPC: C07D417/06 ; C07D417/14 ; A61K31/435 ; A61K31/425
Abstract:
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-isothiazole compounds that, inter alia , inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo , to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.
Information query
